1
The Medical Oncology Course for Surgeons: Fundamentals of Breast Cancer Oncology

The Medical Oncology Course for Surgeons: Fundamentals of Breast Cancer Oncology

SENATURK - MEMORIAL HEALTH GROUP Joint Event

The Medical Oncology Course for Surgeons

Fundamentals of Breast Cancer Oncology

Organized under the Scientific Leadership of Prof. Dr. Bahadır Mahmut Güllüoğlu, Prof. Dr. Mustafa Özdoğan & Doç. Dr. Elvina Almuradova
Memorial Goztepe Cancer Center, Istanbul, Turkiye
DAY I
From Tumor Biology to Treatment Standards
09:00 10:10
SESSION I

Fundamentals of Oncology for Surgeons

  • 09:00 - 09:30 From carcinogenesis to drug discovery
  • 09:30 - 10:00 Breast cancer biology
10:00 - 10:10 Discuss and questions
10:10 10:40
Coffee Break
10:40 12:40
SESSION II

Breast Pathology

  • 10:40 - 11:20 Modern breast pathology: Histological subtypes and grading
  • 11:20 - 11:40 ER, PR, HER2 and Ki-67: clinical implications
  • 11:40 - 12:00 Surgical margins and sentinel lymph node evaluation
  • 12:00 - 12:20 Role of pathology reports in multidisciplinary decision-making
12:20 - 12:40 Discuss and questions
12:40 13:40
Lunch Break
13:40 15:55
SESSION III

Breast Imaging & Intervention

  • 13:40 - 14:10 MG, Breast US and Breast MRI (30 min)
  • 14:10 - 14:40 Radiological assessment of local extent and treatment response (30 min)
  • 14:40 - 15:10 PET-CT applications Prof. Dr. Akın Yıldız (30 min)
  • 15:10 - 15:40 Interventional radiology in breast disease (diagnostic and therapeutic) (30 min)
15:40 - 15:55 Discuss and questions
15:55 16:25
Coffee Break
16:25 17:50
SESSION IV

Principles and Applications of Radiotherapy

  • 16:25 - 17:10 Adjuvant radiation therapy for breast cancer (techniques, treatment fields, fractionation) (45 min)
  • 17:10 - 17:25 Radiation induced side effects: Diagnosis and management (15 min)
  • 17:25 - 17:40 Is there room for de-escalation in selected cases? (15 min)
17:40 - 17:50 Discuss and questions
DAY II
Advanced Strategies & Future Perspectives
08:30 10:00
SESSION V

Mechanisms & Systemic Approaches

  • 08:30 - 08:50 Mechanisms of action of systemic agents
  • 08:50 - 09:20 Systemic therapy in non-metastatic disease (30 min)
  • 09:20 - 09:50 Neoadjuvant versus adjuvant approaches
09:50 - 10:00 Discuss and questions
10:00 10:30
Coffee Break
10:30 11:50
SESSION VI

Metastatic Setting & Patient Monitoring

  • 10:30 - 10:50 Systemic treatment in metastatic disease
  • 10:50 - 11:10 Monitoring treatment response
  • 11:10 - 11:30 Adverse event assessment and management
11:30 - 11:50 Discuss and questions
11:50 13:40
Lunch Break
13:40 16:00
SESSION VII

Precision Medicine & Special Scenarios

  • 13:40 - 14:10 Role of genomic assays and alterations (Comprehensive Genomic Profiling tests, Oncotype DX, MammaPrint, etc.) (30 min)
  • 14:10 - 14:25 Role of genomic assays for precision radiotherapy (Rad Onco)
  • 14:25 - 14:45 ctDNA and its impact on treatment (MRD)
  • 14:45 - 15:45 Multidisciplinary management of oligometastatic disease
    Medical Oncology Perspective (20 min)
    Radiation Oncology Perspective (20 min)
    Surgical Perspective (20 min)
15:45 - 16:00 Discuss and questions
16:00 17:10
CLOSING

Course Conclusions

  • 16:00 - 16:40 Case discussions and interactive Q&A (All Faculty)
  • 16:40 - 17:10 Closing remarks and certificate ceremony (Leadership)

Sağlık ve Mutlulukla Kalın...

Sayfada yer alan yazılar sadece bilgilendirme amaçlıdır, tanı ve tedavi için mutlaka doktorunuza başvurunuz.

İlgili Haberleri


Meme Kanserinde Yeni Bir Üçlü Tedavi: Zovegalisib-Atirmosiklib-Fulvestrant

Meme Kanserinde Yeni Bir Üçlü Tedavi: Zovegalisib-Atirmosiklib-Fulvestrant

Ana kaynak: ReDiscover faz 1 çalışması (NCT05216432) doz bulma kohort...

Meme Kanseri Taramasında Yeni Dönem – ACP 2026 Kılavuzuna Göre 2 Yılda Bir Mamografi

Meme Kanseri Taramasında Yeni Dönem – ACP 2026 Kılavuzuna Göre 2 Yılda Bir Mamografi

Kaynak: Qaseem A ve ark. (American College of Physicians). Screening...

İleri Yaş Meme Kanserinde Cerrahiyi Azaltmak: ctDNA Bir Moleküler Pusula Olabilir mi?

İleri Yaş Meme Kanserinde Cerrahiyi Azaltmak: ctDNA Bir Moleküler Pusula Olabilir mi?

Yaşlı Hastalarda Ameliyatsız Meme Kanseri Takibi: ctDNA ile Güvenli Tedavi...

Meme Kanserinde Yapay Zeka Devrimi: Oncotype DX Sonucunu Patoloji Lamlarından Tahmin Etmek

Meme Kanserinde Yapay Zeka Devrimi: Oncotype DX Sonucunu Patoloji Lamlarından Tahmin Etmek

The Lancet Oncology • Mart 2026 Maliyet ve lojistik bariyerleri...

Hakkımda

Özgeçmişim, kanser tanı ve tedavisine dair çalışmalarım ve ilgi alanlarım için tıklayın.

Prof. Dr. Mustafa Özdoğan Hakkında